Trexquant Investment’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Trexquant Investment’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-59,480	Closed	-$267K	–	1834
2021 Q4	$267K	Buy	59,480 +26,613	+81%	+$126K	0.02%	990
2021 Q3	$160K	Buy	+32,867	New	+$181K	0.01%	998
2021 Q1	–	Sell	-30,781	Closed	-$193K	–	1565
2020 Q4	$193K	Buy	+30,781	New	+$181K	0.02%	894
2018 Q3	–	Sell	-24,336	Closed	-$248K	–	1261
2018 Q2	$248K	Sell	24,336 -16,367	-40%	-$185K	0.02%	736
2018 Q1	$529K	Buy	+40,703	New	+$606K	0.04%	614

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

FIG

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Trexquant Investment's PRTK Position: Q1 2022 in Review

Trexquant Investment sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2022, closing a stake of 59,480 shares — an estimated $267K sold.

Trexquant Investment first reported a position in PRTK in Q1 2018 and held it in 5 quarters. The position peaked at $529K in Q1 2018. 100 funds tracked by Wall St. Rank hold PRTK as of Q1 2022.

Trexquant Investment reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Trexquant Investment sold 59,480 Paratek Pharmaceuticals, Inc. shares in Q1 2022, an estimated $267K.
Trexquant Investment first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2018 and held it in 5 quarters.
Trexquant Investment's Paratek Pharmaceuticals, Inc. position peaked at $529K in Q1 2018.
100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2022.

Based on Trexquant Investment's 13F filing for Q1 2022, filed 13 May 2022.